Author: admin

Intelligent Robotics Market worth $50.33 billion by 2030, at a CAGR of 29.2%

“Intelligent Robotics Market”
The global Intelligent Robotics Market is projected to grow from USD 13.99 billion in 2025 to USD 50.33 billion by 2030 at a CAGR of 29.2% from 2025 to 2030.

The report “Intelligent Robotics Market by Robot Type (Industrial Robots, Service Robots (Ground, Underwater), Collaborative Robots), Mobility (Fixed, Mobile), Application (Personal & Domestic Assistance, Industrial Automation and Region – Global Forecast to 2030” The global intelligent robotics market is anticipated to reach USD 13.99 billion in 2025 and USD 50.33 billion by 2030, growing at a CAGR of 29.2% from 2025 to 2030. The increasing requirement for health services automation acts as a significant driver for the intelligent robotics market. Hospitals and clinics are adopting intelligent robots for surgical help, patient monitoring, and logistics to increase efficiency and accuracy. These robots help reduce human error, support overburdened medical staff, and ensure consistent care delivery. Moreover, the rising labor shortages and the demand for contactless services further reinforce this trend. As a result, intelligent robotics is becoming integral to modern, data-driven healthcare ecosystems.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=99226522

Browse 234 market data Tables and 66 Figures spread through 262 Pages and in-depth TOC on “Intelligent Robotics Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/intelligent-robotics-market-99226522.html

By application, the personal & domestic assistance segment is expected to capture the largest market share in 2030.

The growing consumer interest in home automation solutions such as cleaning, security, and elderly care drives the expansion of the Intelligent Robotics Industry for personal & domestic assistance. The use of AI and voice recognition has improved the functionality and usability of home robots, making them more pervasive and efficient. Aging demographics and urbanization also accelerate the demand for smart caregiving and convenience-driven technologies. With increasing affordability and growing smart home ecosystems, the adoption levels within this category are likely to grow substantially.

In terms of robot type, the collaborative robot’s segment is likely to record a high CAGR from 2025 to 2030.

The market for collaborative robots is expected to grow at a rapid pace during the forecast period. Collaborative robots and their ability to safely work alongside humans without needing safety cages make them ideal for flexible automation in diverse industries. Cobots are finding increasing acceptance across small- and medium-sized enterprises as they are affordable, easy to deploy, and space-saving. Moreover, the combination of AI and sophisticated sensors also enhances their precision, flexibility, and ability to learn. As producers seek scalable and human-collaborative automations, the demand for cobots will grow drastically across sectors, such as electronics, automotive, and logistics.

Asia Pacific is anticipated to hold the largest share of the intelligent robotics market in 2030.

Asia Pacific is set to dominate the intelligent robotics market by 2030, driven by rapid industrialization, strong economic growth, and widespread automation. Countries such as China, Japan, South Korea, and India are heavily investing in robotics and AI to boost manufacturing efficiency and address labor shortages. The surge in e-commerce, particularly in China and India, fuels the demand for intelligent robotics in logistics and delivery. Advanced mobile robotics enhances productivity across sectors such as healthcare, agriculture, and manufacturing. The market dominance is further supported by large-scale production, innovation, supportive government policies, the increasing number of startups, and high R&D investments.

Key Players

Key Players operating in the Intelligent Robotics Companies include Intuitive Surgical (US), iRobot Corporation (US), ECOVACS (China), KUKA AG (Germany), ABB (Switzerland), NVIDIA Corporation (US), Advanced Micro Devices, Inc. (US), HANSON ROBOTICS LTD. (China), Intel Corporation (US), and FANUC CORPORATION (Japan).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/intelligent-robotics-market-99226522.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Intelligent Robotics Market worth $50.33 billion by 2030, at a CAGR of 29.2%

Fresh Thinking for Ag Businesses: A Smarter Way to Connect and Grow

Fresh Thinking for Ag Businesses: A Smarter Way to Connect and Grow
Farm Table’s focused approach to agricultural marketing gives agribusinesses access to practical digital strategies and experienced support, helping them connect with B2B clients more effectively and sustainably in today’s changing landscape.

Agricultural businesses across Australia are facing growing pressure to adapt to changing market conditions, digital expectations, and the evolving needs of B2B clients. In response, more companies are turning to targeted support that understands both marketing and agriculture—a combination that is proving essential in today’s environment.

Farm Table is helping businesses navigate that intersection by offering practical, strategic Ag Marketing solutions tailored to the agricultural sector. As an agricultural marketing agency with roots firmly planted in the rural business landscape, the agency offers services that reflect the real-world challenges and opportunities facing the industry today.

Rather than taking a generic approach to digital marketing, Farm Table focuses on what actually works for agricultural organisations—whether it’s designing clear and useful product catalogues, building effective sales funnels, or crafting content that speaks the language of growers and ag suppliers alike. Campaigns are designed to build trust, generate qualified leads, and drive measurable results, without losing sight of what makes the ag sector unique.

Farm Table’s team brings together a blend of specialists in data analysis, content development, search engine optimisation, public relations, and digital design—all with a shared understanding of agriculture. Their goal is simple: help clients get noticed by the right people, at the right time, using the right tools. From creating SEO-driven websites to developing attention-grabbing social media content, their work supports long-term brand visibility and B2B engagement.

One of the key services offered by Farm Table is digital strategy for agricultural businesses, combining B2B experience with a deep understanding of seasonal trends, buyer behaviour, and rural industry dynamics. Whether it’s a new product launch, a refreshed brand identity, or a campaign to expand regional presence, the team focuses on delivering solutions that are timely, relevant, and easy to implement. Their approach to Ag Marketing ensures that every strategy is grounded in agricultural context and business reality.

In addition to campaign management and digital marketing, Farm Table offers tailored advice and planning support. Clients benefit from a network of professionals who understand the long sales cycles common in agribusiness and the importance of building strong, ongoing relationships rather than short-term gains. The agency also provides support with media relations, including connections to print, broadcast, and online platforms across the agricultural sector.

Based in Australia, Farm Table was established to bridge the knowledge and communication gap between ag-focused businesses and the wider market. As an independent platform and marketing partner, it brings together tools, insights, and resources from across the industry to create a collaborative space for producers, suppliers, and organisations. Farm Table’s mission is to help rural businesses thrive by giving them the Ag marketing support they need, when and where they need it—without the jargon or one-size-fits-all approach.

Media Contact
Company Name: Farm Table
Contact Person: Rob Jennings
Email: Send Email
Phone: 03 70442185
Address:Two Melbourne Quarter, Ground Floor/697 Collins St
City: Docklands
State: VIC 3008
Country: Australia
Website: https://farmtable.com.au/

Cash Flow Builder Group Expands Business Lending Access Under the Visionary Leadership of Tiffany Nguyen

Cash Flow Builder Group, led by CEO Tiffany Nguyen, is expanding access to business lending for entrepreneurs nationwide. Based in Houston, the firm connects clients with over 50 funding sources, offering tailored solutions from $100,000 to $10 million. Through a consultative approach, Cash Flow Builder Group increases approval rates and empowers businesses with clarity, confidence, and strategic financial support.

In an era marked by economic uncertainty and evolving financial landscapes, small businesses are increasingly challenged by limited access to flexible and reliable capital. Addressing this critical need, Cash Flow Builder Group, a Houston-based business funding consultancy, is making significant strides in bridging the gap between entrepreneurs and strategic lending solutions. Under the dynamic leadership of founder and Chief Executive Officer Tiffany Nguyen, the firm is redefining how businesses secure the capital necessary for growth and sustainability.

Founded by Tiffany Nguyen, a seasoned business advisor renowned for her expertise in credit structuring and small business financing, Cash Flow Builder Group has rapidly established itself as a trusted partner for businesses across a diverse range of industries. From retail and hospitality to early-stage startups, the firm’s client base reflects its commitment to supporting the unique needs of entrepreneurs at every stage of development.

Cash Flow Builder Group distinguishes itself through an extensive network of over 50 funding sources, including banks, private lenders, and innovative fintech partners. This robust portfolio enables the firm to facilitate access to capital ranging from $100,000 to $10 million, ensuring that clients can secure the resources required to achieve their business objectives. The firm’s comprehensive suite of services encompasses working capital loans, equipment financing, marketing funds, and acquisition capital, each meticulously tailored to align with the client’s specific business model and long-term goals.

What sets Cash Flow Builder Group apart from traditional brokers is its consultative and client-centric approach. Entrepreneurs who engage with the firm benefit from a thorough funding assessment, detailed credit review, and professional documentation preparation prior to being matched with suitable lending partners. This rigorous process not only increases approval rates but also ensures that clients receive the most favorable loan terms available in the market.

“Tiffany Nguyen brings a strategic, personalized lens to every deal,” stated a company representative. “Our mission is to remove complexity from the funding process and connect the right clients to the right funding at the right time. We are dedicated to empowering business owners with the clarity, confidence, and connections they need to thrive.”

Clients who partner with Cash Flow Builder Group consistently report higher approval success, enhanced financial clarity, and sustainable capital growth. In a business environment characterized by rapidly shifting funding standards, the firm remains a steadfast and reliable bridge between opportunity and execution.

As the demand for flexible business capital continues to rise, Cash Flow Builder Group stands at the forefront of innovation in business lending. Under Tiffany Nguyen’s visionary leadership, the firm is committed to empowering entrepreneurs nationwide, providing them with the tools and resources necessary to navigate today’s complex financial landscape with confidence.

Media Contact
Company Name: Cash Flow Builder Group
Contact Person: Tiffany Nguyen, Chief Executive Officer
Email: Send Email
Phone: (936) 445-6979
Country: United States
Website: https://cashflowbuildersgroup.com/

Tolga Cakir Announces the 2025 Edition of Bestselling Guide: How to Start an Online Business in 7 Steps

New edition delivers fresh, practical strategies to empower aspiring entrepreneurs worldwide.

London, UK – July 21, 2025 – Tolga Cakir, Amazon’s number one bestselling author and seasoned entrepreneur, is proud to announce the release of the 2025 edition of his acclaimed book, How to Start an Online Business in 7 Steps. Designed specifically for non-technical readers around the globe, this updated edition brings modern, actionable insights to help anyone launch and grow a successful online business.

Building on the success of the original bestseller in the UK, USA, and Australia, Tolga Cakir leverages his extensive professional experience — from administrative roles at British Gas and management positions at major UK banks, to digital consultancy for SMEs and strategic AI integration — to guide readers through the evolving digital landscape with clarity and confidence.

This practical guide breaks down complex online business concepts into plain language, making it accessible for entrepreneurs at any stage, regardless of their technical background. Readers will discover essential steps to identify business opportunities, build an effective online presence, attract customers, and scale sustainably in the digital marketplace.

“Starting an online business feels overwhelming for many, especially without a technical foundation,” said Tolga Cakir. “My goal with this book is to demystify the process and provide a clear, step-by-step roadmap that anyone can follow to unlock their entrepreneurial potential and harness today’s digital tools.”

Beyond his writing, Tolga is a certified transformational coach, commercial drone pilot, and a passionate advocate for innovation, clean oceans, and happiness psychology. His diverse academic background includes studies at Harvard, Oxford, Leeds Metropolitan University and the University of Leeds.

How to Start an Online Business in 7 Steps (2025 Edition) is soon available for pre-order with a scheduled release on 30th August 2025.

For more information, interview requests, or media inquiries, please contact: https://tolgacakir.com/contact-us

Social Media: https://www.linkedin.com/in/tolgacakir

Contact Tolga

Media Contact
Company Name: Black Eagle Publishing Ltd.
Contact Person: Bill
Email: Send Email
Phone: +447506757334
Country: United Kingdom
Website: https://tolgacakir.com

Hemorrhagic Cystitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | GSK, AlloVir, Lipella Pharma, Novo Nordisk A/S

The Key Hemorrhagic Cystitis Companies in the market include – GSK, AlloVir, Lipella Pharmaceuticals, Novo Nordisk A/S, and others.

 

DelveInsight’s “Hemorrhagic Cystitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hemorrhagic Cystitis, historical and forecasted epidemiology as well as the Hemorrhagic Cystitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Hemorrhagic Cystitis, offering comprehensive insights into the Hemorrhagic Cystitis revenue trends, prevalence, and treatment landscape. The report delves into key Hemorrhagic Cystitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Hemorrhagic Cystitis therapies. Additionally, we cover the landscape of Hemorrhagic Cystitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Hemorrhagic Cystitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Hemorrhagic Cystitis space.

 

To Know in detail about the Hemorrhagic Cystitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemorrhagic Cystitis Market Forecast

 

Some of the key facts of the Hemorrhagic Cystitis Market Report:

  • The Hemorrhagic Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • Key Hemorrhagic Cystitis Companies: GSK, AlloVir, Lipella Pharmaceuticals, Novo Nordisk A/S, and others

  • Key Hemorrhagic Cystitis Therapies: Gepotidacin, Posoleucel, LP-10, activated recombinant human factor VII, and others

  • The Hemorrhagic Cystitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemorrhagic Cystitis pipeline products will significantly revolutionize the Hemorrhagic Cystitis market dynamics.

  • Incidence in Cancer Patients Occurs in 5–10% of patients receiving cyclophosphamide or ifosfamide-based chemotherapy.

  • Radiation-Induced HC Affects up to 20% of patients undergoing pelvic radiation therapy, with symptoms appearing months to years after treatment.

  • HC in Bone Marrow Transplant Recipients Found in 7–30% of hematopoietic stem cell transplant (HSCT) patients, often due to viral infections or conditioning regimens.

  • Viral HC Cases BK virus-associated hemorrhagic cystitis is common in 10–25% of immunocompromised patients, especially after organ transplants.

  • Pediatric Incidence is more frequent in children undergoing chemotherapy or radiation, with incidence rates ranging from 5–20%.

  • Severity-Based Mortality Risk Severe cases with uncontrolled bleeding and urinary obstruction significantly increase morbidity and mortality risks.

 

Hemorrhagic Cystitis Overview

Hemorrhagic Cystitis is a condition characterized by inflammation of the bladder accompanied by bleeding. It can cause painful urination, blood in the urine (hematuria), urinary urgency, and bladder discomfort. The condition may result from chemotherapy (especially cyclophosphamide or ifosfamide), radiation therapy, viral infections (like BK virus), or exposure to certain toxins. Treatment involves hydration, bladder irrigation, pain management, and addressing the underlying cause. In severe cases, more advanced interventions like intravesical therapy or surgery may be needed.

 

Get a Free sample for the Hemorrhagic Cystitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market

 

Hemorrhagic Cystitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hemorrhagic Cystitis Epidemiology Segmentation:

The Hemorrhagic Cystitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hemorrhagic Cystitis

  • Prevalent Cases of Hemorrhagic Cystitis by severity

  • Gender-specific Prevalence of Hemorrhagic Cystitis

  • Diagnosed Cases of Episodic and Chronic Hemorrhagic Cystitis

 

Download the report to understand which factors are driving Hemorrhagic Cystitis epidemiology trends @ Hemorrhagic Cystitis Epidemiology Forecast

 

Hemorrhagic Cystitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemorrhagic Cystitis market or expected to get launched during the study period. The analysis covers Hemorrhagic Cystitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemorrhagic Cystitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hemorrhagic Cystitis Therapies and Key Companies

  • Gepotidacin: GSK

  • Posoleucel: AlloVir

  • LP-10: Lipella Pharmaceuticals

  • activated recombinant human factor VII: Novo Nordisk A/S

 

Discover more about therapies set to grab major Hemorrhagic Cystitis market share @ Hemorrhagic Cystitis Treatment Landscape

 

Hemorrhagic Cystitis Market Drivers

  • Increasing Use of Chemotherapy & Radiation Therapy

  • Advancements in Bladder Protective Therapies

  • Growing Awareness & Early Diagnosis

  • Rising Organ Transplantation Cases

  • Improved Healthcare Infrastructure

 

Hemorrhagic Cystitis Market Barriers

  • High Treatment Costs

  • Limited Awareness in Developing Regions

  • Adverse Effects of Existing Therapies

  • Lack of Targeted Therapies

  • Regulatory Challenges in Drug Approvals

 

Scope of the Hemorrhagic Cystitis Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Hemorrhagic Cystitis Companies: GSK, AlloVir, Lipella Pharmaceuticals, Novo Nordisk A/S, and others

  • Key Hemorrhagic Cystitis Therapies: Gepotidacin, Posoleucel, LP-10, activated recombinant human factor VII, and others

  • Hemorrhagic Cystitis Therapeutic Assessment: Hemorrhagic Cystitis current marketed and Hemorrhagic Cystitis emerging therapies

  • Hemorrhagic Cystitis Market Dynamics: Hemorrhagic Cystitis market drivers and Hemorrhagic Cystitis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Hemorrhagic Cystitis Unmet Needs, KOL’s views, Analyst’s views, Hemorrhagic Cystitis Market Access and Reimbursement

 

To know more about Hemorrhagic Cystitis companies working in the treatment market, visit @ Hemorrhagic Cystitis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Hemorrhagic Cystitis Market Report Introduction

2. Executive Summary for Hemorrhagic Cystitis

3. SWOT analysis of Hemorrhagic Cystitis

4. Hemorrhagic Cystitis Patient Share (%) Overview at a Glance

5. Hemorrhagic Cystitis Market Overview at a Glance

6. Hemorrhagic Cystitis Disease Background and Overview

7. Hemorrhagic Cystitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemorrhagic Cystitis

9. Hemorrhagic Cystitis Current Treatment and Medical Practices

10. Hemorrhagic Cystitis Unmet Needs

11. Hemorrhagic Cystitis Emerging Therapies

12. Hemorrhagic Cystitis Market Outlook

13. Country-Wise Hemorrhagic Cystitis Market Analysis (2019–2032)

14. Hemorrhagic Cystitis Market Access and Reimbursement of Therapies

15. Hemorrhagic Cystitis Market Drivers

16. Hemorrhagic Cystitis Market Barriers

17. Hemorrhagic Cystitis Appendix

18. Hemorrhagic Cystitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemorrhagic Cystitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | GSK, AlloVir, Lipella Pharma, Novo Nordisk A/S

Jonathan McKinney Calls for Community Action in Support of Overwhelmed Foster Families

Jonathan McKinney Calls for Community Action in Support of Overwhelmed Foster Families

Jonathan McKinney, Tuscaloosa, Alabama
Tuscaloosa Builder Urges Others to Identify and Meet Local Needs Through Service

Jonathan McKinney, longtime homebuilder and founder of AIP Construction, is using his platform to raise awareness about the growing strain on foster families and under-resourced support spaces in Alabama. Drawing on years of volunteer work through Church of the Highlands, Jonathan McKinney is urging everyday citizens to take simple, direct action in their own communities.

“We’re not talking about huge things. Just needs that often go unseen,” McKinney says. “One year, a foster family I knew had more children than bedrooms. So we built a room. That changed what was possible for them. It’s not a government fix. It’s neighbors helping neighbors.”

According to Alabama’s Department of Human Resources, there are over 5,700 children in foster care statewide. Many families are willing to open their homes, but lack the space or resources. In addition, visitation rooms—where children meet with biological parents—are often underfunded and poorly maintained, creating stressful environments for already fragile interactions.

“That’s why we remodeled a DHR visitation space,” McKinney explains. “It needed warmth. A couch. Some color. We made it feel human again.”

These projects aren’t one-offs. McKinney and a team of volunteers lead a new service initiative every July. In past years, they’ve:

  • Refurbished church basements for student groups near the University of Alabama

  • Painted cabins at a rehabilitation facility

  • Built extra rooms for overburdened foster homes

All of these projects are paid for out-of-pocket and staffed with volunteers.

“You don’t need a nonprofit or a grant to do this,” McKinney says. “You just need to see a need and say, ‘Let’s fix that.’”

While his business, AIP Construction, keeps him busy year-round, McKinney emphasizes that meaningful impact doesn’t require spare time—just a mindset.

“Everyone has skills. Everyone has something they can offer. Start with what’s right in front of you.”

He’s hoping more community leaders, churches, and small business owners will look for similar needs in their areas—whether it’s rehabbing a shelter, donating time to local schools, or supporting families in crisis.

“You don’t have to do everything. But you can do something. And that matters.”

Why It Matters

  • Over 5,700 children are currently in Alabama’s foster care system

  • Only about half of counties in Alabama have enough foster homes to meet demand

  • Many DHR visitation rooms are unrenovated, despite being central to family reunification plans

  • Studies show environmental quality significantly impacts outcomes for children in crisis

Identify a need. Make a plan. Rally your people. Build something that lasts.

Whether you’re a builder, a teacher, or a parent—your time and effort can help families stay connected and supported. Jonathan McKinney invites you to look around your community and ask one question:

“What’s something we can fix right now?”

Media Contact
Contact Person: Joanthan McKinney
Email: Send Email
City: Tuscaloosa
State: Alabama
Country: United States
Website: https://www.jonathanmckinneyconstruction.com/

The 17th Global Chinese Awards Ceremony Held in Beijing

BEIJING – July 21, 2025 – The 17th Global Chinese Awards ceremony, titled “You Bring Charm to the World,” sponsored by Guojiao 1573, concluded successfully tonight at the Phoenix Satellite TV headquarters in Beijing. The winners of the Lifetime Achievement Award, Special Tribute Award, and other major accolades shared their inspiring stories, celebrating Chinese excellence and honor.

Xu Wei, Chairman and CEO of Phoenix Satellite TV, said in his speech that the Global Chinese Awards has consistently documented the real journeys of Chinese people from a global perspective, exploring the cultural essence of the Chinese spirit and conveying the warmth and power of Chinese culture. He noted that this year’s awardees embody unwavering self-motivation and a strong sense of unity among Chinese communities worldwide, showcasing the unique charm of Chinese culture.

Turing Award laureate Yao Qizhi, an academician of the Chinese Academy of Sciences, and Dean of the Institute for Interdisciplinary Information Sciences and the Institute of Artificial Intelligence at Tsinghua University, received the Global Chinese Awards Lifetime Achievement Award. The award was presented by Xu Wei. In his remarks, Yao Qizhi stated, “I’ve been engaged in scientific research for over 50 years, and it’s a fascinating and meaningful endeavor. I am grateful for the opportunity to contribute even a small part to this great cause.” He also expressed special thanks to his wife, Chu Feng, who was present at the ceremony, for her many years of support and companionship.

Renowned writer and producer Bai Xianyong, best known for the youth-edition Kunqu The Peony Pavilion, was honored with the Global Chinese Awards Special Tribute Award. He entrusted Xiang Yong, a professor at the Peking University School of Arts and Dean of the Institute for Cultural Industries, to accept the award on his behalf. In a video message, Bai Xianyong said, “I call myself the ‘captain of the Kunqu Opera volunteers,’ but in reality, there is a large group of friends behind me who are passionate about preserving Chinese culture. They have been incredibly supportive and deeply involved. I accept this honor on behalf of the entire The Peony Pavilion team.”

Chen Qingquan, the first Hong Kong-based academician of the Chinese Academy of Engineering and distinguished chair professor at The Hong Kong Polytechnic University, received a Global Chinese Award. The award was presented by He Xi, Chairman of China Power International Development Limited. Chen Qingquan said, “Future electric vehicles will become humanity’s ‘third space,’ significantly improving our quality of life and well-being. Our work on electric vehicles is not only to benefit the Chinese people but also the entire world, for this generation and those to come.

Actor and singer Fei Xiang was presented with a Global Chinese Award by Chen Jianhui, Vice President of China News Service. In his acceptance speech, Fei Xiang shared, “I love the theme of the awards, ‘You Bring Charm to the World,’ because the value of every individual is connected to the world. Everyone contributes to making the world a better place.” He concluded by expressing gratitude to the audiences who have supported and encouraged him over the years.

Xu Jingkun, a global sailor and the first Chinese person to complete the Vendée Globe solo non-stop round-the-world race, was presented with a Global Chinese Award by Tang Dongliang, Executive Vice General Manager of Luzhou Laojiao Co., Ltd. Xu Jingkun shared highlights of his journey with a few key numbers: 27,616 nautical miles sailed over 99 days and climbing the 29-meter mast three times in a single day. He became the 100th person to finish the race, often called the “Mount Everest of sailing.” Reflecting on his achievement, he said, “Chinese navigation has never been absent from history, and new routes are never found by waiting.”

The team of young builders of the Chinese Space Station received a Global Chinese Award. Yang Liwei, Deputy Chief Designer of the China Manned Space Program and national space hero, presented the award to eight representatives. Yang Liwei said, “The average age of the core team for the Chinese space station project is under 30. The future of China’s space program belongs to the younger generation.”

The Chinese national table tennis team was also honored with a Global Chinese Award, presented by Xu Zhengzhong, Chairman of Bauhinia Culture Group. The team’s head coach, Li Sun, accepted the award on their behalf. Li Sun emphasized that the team’s success reflects the combined efforts of multiple generations and that bringing glory to the nation has always been the shared dream and goal of Chinese table tennis players.

The “You Bring Charm to the World” Global Chinese Awards ceremony was initiated by the Phoenix Satellite TV Group in partnership with several Chinese-language media organizations at home and abroad. The event celebrates Chinese role models who have achieved outstanding success and global influence across diverse fields. Over the past decade, more than 100 exceptional Chinese individuals have been recognized at this event.

Media Contact
Company Name: Phoenix TV
Contact Person: Caoyuxuan
Email: Send Email
Country: China
Website: https://www.fengshows.com

Edit Lobby Helps Creators Build Their Careers as Industry is Expected to Hit Half a Trillion Dollars by 2027

As the creator economy is set to reach $500 billion within two years, skillfully edited videos will become more necessary for successful social media careers. Edit Lobby allows everyone to access fast, professional video editing to tell their stories.

While many once dismissed the creator economy as a “niche side hustle market,” it is on track to earn half a trillion dollars by 2027, according to recent industry reports. However, even the most popular influencers can be lost in the endless sea of creators without visually appealing, interesting video editing that showcases their work in its best light. Anyone can learn to edit videos properly, but one company is fueling the momentum—Edit Lobby. This quietly powerful player is behind the recent surge of polished short-form videos, viral storytelling, and digital-first brands, with many more expected to join the Edit Lobby community as the industry continues to grow.

“Video editing was never supposed to be a task,” said Edit Lobby Co-Founder Nihal Ruparel. “It was always just a tool for effective storytelling. People just made it harder.”

Edit Lobby is the ideal post-production powerhouse for content creators, entrepreneurs, and creative agencies. The company was founded on a mission to democratize access to premium video editing, and its work is leading to systemic change and life-altering growth for creators. From TikTok stars and YouTube educators to rapidly growing DTC brands, Edit Lobby sits at the intersection of creative vision and scalable content execution.

“We realized that creators weren’t just looking for an editor, they needed a system,” Ruparel said. “A platform that’s fast, intuitive, and built by people who get content. That’s what we build with Edit Lobby.”

With Edit Lobby on their teams, creators can experience editing at the speed of culture, with styles, methods, and video editing that match the latest trend—or create the next one. Content trends shift daily, and audience attention spans seem to shrink, leaving creators under pressure to produce and perform faster than ever.

Edit Lobby helps clients solve a major bottleneck by offering on-demand, studio-grade editing with turnaround times as fast as 48 hours. The company provides access to a curated team of seasoned editors, AI-assisted workflows, and human-led quality control, making it a favorite among creators who prioritize speed and storytelling.

“Our goal was to create a service that matched the quality of a high-end studio, but with the speed and accessibility creators actually need.” said Edit Lobby Co-Founder and Creative Director Yoshitha Challapalli.

Over 50 million independent content creators monetize their work online, leading to a skyrocketing demand for post-production support. However, not every creator has access to a full production team—that’s where Edit Lobby levels the playing field.

Edit Lobby offers affordable monthly plans and individual edits tailored for individuals, teams, and agencies, enabling creators to outsource video editing without compromising quality or creative control.

Edit Lobby was built by editors, for creators, setting it apart by showing the difference expertise makes in every frame, transition, and beat drop. As brands, influencers, and solo entrepreneurs seek to stake their claim in the fast-growing creator economy, Edit Lobby is on standby as their secret weapon.

“Being a creator or running a brand today means showing up with the right visuals, consistently,” Challapalli said. “That’s why Edit Lobby handles all your video editing needs in one place, so you can focus on growing, not juggling editors.”

Visit the Edit Lobby website to learn more about the company powering the content behind the clicks, the conversions, and the culture. Schedule a consultation with the Edit Lobby team for professional video editing from the basic or premium collection.

Media Contact
Company Name: Edit Lobby
Contact Person: Nihal Ruparel
Email: Send Email
Country: United States
Website: https://editlobby.com/

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA

The Key Sickle Cell Disease Companies in the market include – Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others.

 

DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom.

 

To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast

 

Some of the key facts of the Sickle Cell Disease Market Report:

  • Among the 6MM countries the Sickle Cell Disease market size was valued ~USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12–15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs).

  • In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide—both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)—has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy.

  • In June 2024, Vertex Pharmaceuticals shared long-term results for its gene therapy, Casgevy (exa-cel), in patients with sickle cell disease or transfusion-dependent beta-thalassemia (TDT).

  • In 2023, the United States held the largest market share for Sickle Cell Disease among the 6MM, with approximately USD 603 million, followed by France and the UK.

  • At present, treatments for Sickle Cell Disease include NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Additionally, the US FDA has approved several therapies for this condition, such as DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor).

  • In 2023, the United States had the largest total number of prevalent Sickle Cell Disease cases among the 6MM.

  • In the US, Sickle Cell Anemia (hemoglobin S/S or hemoglobin S/β0-thalassemia) was the most common subtype of Sickle Cell Disease among the type-specific prevalent cases in 2023.

  • In the EU4 and the UK, France had the highest prevalence of Sickle Cell Disease cases, followed by the UK, while Spain reported the lowest number of cases.

  • Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

  • Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

  • The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

  • The Sickle Cell Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.

 

Sickle Cell Disease Overview

Sickle cell disease (SCD) comprises inherited red blood cell disorders resulting from an abnormality in the structure of hemoglobin known as sickle hemoglobin (HbS), which encodes the beta hemoglobin subunit.

 

Get a Free sample for the Sickle Cell Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sickle-cell-disease-market

 

Sickle Cell Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Sickle Cell Disease

  • Prevalent Cases of Sickle Cell Disease by severity

  • Gender-specific Prevalence of Sickle Cell Disease

  • Diagnosed Cases of Episodic and Chronic Sickle Cell Disease

 

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiology Forecast

 

Sickle Cell Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Sickle Cell Disease Therapies and Key Companies

  • CASGEVY (exagamglogene autotemcel): Vertex Pharmaceuticals/CRISPR Therapeutics

  • ENDARI (L-glutamine): Emmaus Life Sciences

  • Mitapivat: Agios Pharmaceuticals

  • Inclacumab: Pfizer

  • GMI-1687: Glycomimetics

  • BIVV003: Sanofi

  • CSL889: CSL Behring

  • Siplizumab: ITB-Med LLC

  • Etavopivat Tablets: Novo Nordisk A/S

  • VIT-2763: Fortrea, Inc.

  • Crizanlizumab: Novartis

  • Epeleuton: Afimmune

  • Voxelotor: Pfizer

  • Hydroxycarbamide: ADDMEDICA SASA

  • Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

  • Mitapivat: Agios Pharmaceuticals

  • Canakinumab: Novartis

  • ALXN1820: Alexion Pharmaceuticals

  • Crovalimab: Chugai Pharmaceutical/Roche

  • EDIT 301: Editas Medicine

  • BIVV003: Sangamo Therapeutics

  • BEAM101: Beam Therapeutics

  • Hemopexin: CSL Behring

 

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape

 

Scope of the Sickle Cell Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]

  • Key Sickle Cell Disease Companies: Vertex Pharmaceuticals/CRISPR Therapeutics, Pfizer, Glycomimetics, Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics/Vertex Pharmaceuticals, Agios Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical/Roche, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, CSL Behring, and others

  • Key Sickle Cell Disease Therapies: CASGEVY (exagamglogene autotemcel), Inclacumab, GMI-1687, BIVV003, CSL889, Siplizumab, Etavopivat Tablets, VIT-2763, Crizanlizumab, Epeleuton, Voxelotor, Hydroxycarbamide, Exagamglogene autotemcel, Mitapivat, Canakinumab, ALXN1820, Crovalimab, EDIT 301, BIVV003, BEAM101, Hemopexin, and others

  • Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

  • Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Sickle Cell Disease Unmet Needs, KOL’s views, Analyst’s views, Sickle Cell Disease Market Access and Reimbursement

 

To know more about Sickle Cell Disease companies working in the treatment market, visit @ Sickle Cell Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2020–2034)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market Drivers

16. Sickle Cell Disease Market Barriers

17. Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA

Legal Tax Defense Announces Expanded Services for Tax Debt Relief

Experienced Tax Attorneys Provide Tailored Support for Individuals and Businesses Facing IRS Challenges


Legal Tax Defense, Inc. Logo

Los Angeles, CA – Legal Tax Defense, Inc., a trusted name in tax law representation, announces the expansion of its services through the addition of new legal staff, updated client support systems, and specialized offerings addressing ERC audits, and multi-state tax issues. With a team of seasoned tax attorneys and enrolled agents, Legal Tax Defense continues to offer personalized tax debt relief solutions designed to protect clients from aggressive collection actions and financial strain.

In recent years, an increasing number of Americans have faced mounting tax debt as a result of economic disruptions and evolving IRS enforcement measures.Legal Tax Defense has responded by hiring additional legal professionals and client service specialists, reducing wait times for initial consultations. The firm also launched a new secure client portal to streamline document submissions and communications, and expanded its availability to include evening and weekend appointments.

“Tax debt can create long-term financial distress for families and business owners alike,” said a spokesperson for Legal Tax Defense. “Our mission is to offer clear, honest legal representation so that taxpayers understand their rights and are not left navigating the IRS alone.”

Legal Tax Defense provides comprehensive legal services that include Offers in Compromise, installment agreements, penalty abatement requests, and audit defense. Clients receive support from licensed professionals who are well-versed in federal and state tax laws, ensuring compliance while pursuing the most favorable outcomes.

As part of the expanded services, the firm now offers tailored solutions for emerging tax concerns, including Employee Retention Credit (ERC) audit defense, and support for remote workers facing multi-state filing obligations. These additions reflect the evolving landscape of tax enforcement and the firm’s commitment to staying ahead of regulatory changes.

All case evaluations begin with a detailed review of each client’s financial circumstances to determine the most appropriate path toward resolution. The firm operates with a commitment to confidentiality, transparency, and clear communication throughout the process.

With its expanded focus, Legal Tax Defense aims to reach more individuals and businesses across the United States who are in need of reliable tax debt relief. The firm also offers educational resources on its website, www.legaltaxdefense.com, helping taxpayers understand their options and avoid common pitfalls when dealing with the IRS.

Legal Tax Defense is headquartered in Los Angeles and serves clients nationwide through virtual consultations and secure document handling systems.

For more information or to schedule a consultation, visit www.legaltaxdefense.com.

About Legal Tax Defense, Inc.

Legal Tax Defense, Inc. is a Los Angeles-based tax law firm dedicated to helping individuals and businesses resolve complex tax issues with the IRS and state tax agencies. With a team of experienced tax attorneys, enrolled agents, and case specialists, the firm provides comprehensive services including tax debt relief, audit representation, Offers in Compromise, and installment agreements. Legal Tax Defense is committed to transparency, ethical advocacy, and personalized legal strategies that protect clients’ financial futures. The firm serves clients nationwide through secure virtual consultations. To learn more, visit www.legaltaxdefense.com.

Disclaimer: This press release is intended for informational purposes only. Tax laws vary by jurisdiction, and individuals are advised to consult a licensed tax attorney or professional regarding their specific situation.

Media Contact
Company Name: Legal Tax Defense, Inc.
Contact Person: Sharon Goldstein-Shapiro
Email: Send Email
Phone: 800-804-2769
Country: United States
Website: https://www.legaltaxdefense.com/